Overview

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

Status:
Terminated

Trial end date:
2003-05-01

Target enrollment:

Participant gender:

Summary

To determine safety and efficacy of ACH-126,443 on the treatment of adults with HIV infection who have modestly detectable viral load while on stable triple combination antiretroviral therapy including 3TC.

Phase:

Phase 2

Details

Lead Sponsor:

Achillion Pharmaceuticals
Alexion Pharmaceuticals

Treatments:

Dexelvucitabine